Roche Says Phase III CELESTIMO Study Meets Primary Endpoint With Clinically Meaningful Reduction In Disease Progression Risk For Follicular Lymphoma Patients

Roche's Phase III CELESTIMO study has met its primary endpoint, showing a statistically significant reduction in disease progression risk for follicular lymphoma patients who have undergone prior treatment. The results highlight the potential of the Lunsumio-based regimen to enhance clinical outcomes with a favorable safety profile and convenient administration. Roche plans to submit the data to health authorities and present it at an upcoming medical meeting.